Introduction
Fibrosis is a common consequence of injury leading to failure in many organs. Cardiac fibrosis is an integral part of adverse remodelling leading to alterations in diastolic distensibility, arrhythmia, and systolic failure. 1 In humans, the absence of recovery of LV function after aortic valve replacement correlates with the degree of fibrosis. 2, 3 Although myocardial fibrosis can be reversed in some cases, 4 targeted therapies remain largely elusive. Recent lineage tracing experiments have identified specific populations of fibroblasts that contribute myocardial fibrosis. 5, 6 They concluded to a major participation of resident cardiac fibroblasts developmentally deriving from epicardium or endocardial endothelium. 6 Upon pressure overload, local proliferation and subsequent myodifferentiation of these resident fibroblasts produce myocardial fibrosis, emphasizing the importance of signalling within 'fibrogenic niches '. 7 This involves reciprocal paracrine signalling between parenchymal and neighboring cells. Although much attention has been focused on the influence of fibroblasts in regulating cardiac myocytes hypertrophy, little attention has been devoted so far to signals sent from 'stressed' myocytes to fibroblasts. Beta3AR are expressed in human atrial and ventricular myocytes, 8 in which their contractile effects are antipathetic to those of beta1-2AR. 9 Although prolonged activation or high heterologous expression of beta1AR exacerbates adverse myocardial remodelling, 10 this opposing effect of beta3AR suggests unique protective properties for this isotype. 11 However, the underlying mechanisms, particularly through paracrine signalling, remain undefined. In the present work, we use genetic mouse models with cardiac myocyte-specific expression of ADRB3 or conditional deletion of Adrb3 to study the receptor's specific role in myocardial protection from fibrosis in response to transaortic constriction (TAC). Using a model of superfusion of cardiac fibroblasts incubated with media conditioned by cardiac myocytes adenovirally-expressing ADRB3, combined with unbiased proteomic analysis of their secretome, we identify a number of beta3AR-regulated signalling or matricellular proteins that modulate the activation of fibroblasts. Among these, we found that connective tissue growth factor (CTGF)/CCN2 expression was downregulated by beta3AR through its coupling to neuronal nitric oxide synthase (nNOS) and anti-oxidant effects in cardiac myocytes.
Methods
Expanded methods are available in the Supplementary material online.
Results
Expression of the beta3-adrenergic receptors in cardiac myocytes protects from myocardial fibrosis under haemodynamic overload
Heterozygous adult mice harbouring a transgene coding the human ADRB3 under the Myh6 (alpha-Myosin Heavy Chain, alpha-MHC) promoter (ADRB3-tg) were subjected to TAC and their phenotype analysed at 9 weeks post-TAC. Morphometric data are illustrated in Figure 1A . Note that, in our model, the abundance of transgenic human beta3AR proteins was comparable to that observed in human ventricular extracts (see Supplementary material online, Figure S1G ) and that transcripts levels of Adrb1 and Adrb2 were unchanged between ADRB3-tg and WT, both at baseline and after TAC (see Supplementary material online, Figure S1A and B). All mice included in the study (ADRB3-tg and WT) developed a trans-stenotic gradient with maximum velocity (by Doppler echo) of at least 3 m/s, and gradients were comparable between genotypes (see Supplementary material online, Figure S2 ). ADRB3-tg mice developed a moderate hypertrophic response which was significantly milder than WT ( Figure 1A) . Histological analysis showed that myocardial fibrosis was strikingly attenuated in ADRB3-tg ( Figure 1B) . This was confirmed by quantification of collagen volume fraction, as well as of collagen type 1 both by immunohistochemical analysis and western blotting ( Figure 1C and D) . Capillary density and inflammatory cells (CD45 þ )
infiltration were comparable between genotypes. No differences in apoptosis were observed between genotypes 9 weeks post-TAC (see Supplementary material online, Figure S3 ).
To further confirm the causal role of the cardiac Adrb3, we analyzed the phenotype of mice with cardiac myocyte-specific deletion of the mouse Adrb3 using an inducible Cre-lox system. Mice with exon 2 of Adrb3 flanked by 2 lox-P sites were generated and back-crossed in the C57Bl/6J background for at least 9 generations, then cross-bred with mice (in C57Bl/6J background) expressing a tamoxifen-inducible Cre recombinase under the alpha-MHC promoter (alpha-MHCMerCreMer) (Figure 2A) . Double-transgenic mice were then treated with tamoxifen and underwent TAC (or sham operation) and their cardiac remodelling analysed. We previously tested several treatment schemes with tamoxifen to ensure efficient recombination while avoiding any independent effect of tamoxifen on hypertrophic or fibrotic remodelling. Tamoxifen alone at 30 lg/g body weight/day injected on three consecutive days produced an efficient recombination
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. and double-transgenic mice without tamoxifen were submitted to TAC (or sham) in parallel as controls. Note that transcripts levels of Adrb1 and Adrb2 were unchanged between single or double transgenics with tamoxifen, both at baseline and after TAC (see Supplementary material online, Figure S1C and D). As expected, single transgenic mice and double transgenics without tamoxifen developed TAC-induced hypertrophy ( Figure 2B ) and fibrosis ( Figure  2C -E) to a comparable extent. However, after tamoxifen treatment, double transgenics developed similar hypertrophy ( Figure 2B ) but a higher degree of fibrosis compared with all other controls (including double transgenics without tamoxifen) (see Supplementary material online, Figure C -E). This included higher collagen volume fraction ( Figure 2C ), increased collagen type I ( Figure 2D ) and type III ( Figure 2E ). Expression of beta3-adrenergic receptors regulates paracrine signalling from cardiac myocytes to fibroblasts
As the expression of the beta3AR in our transgenic models was either upregulated or deleted specifically in cardiac myocytes (CM), and in absence of changes in apoptosis, we reasoned that the fibrotic phenotype may have resulted from altered paracrine signalling between these cells and neighboring fibroblasts. To examine this hypothesis, we developed an in vitro superfusion model ( Figure 3A ) in which cardiac fibroblasts were incubated in culture media conditioned by CM expressing (or not) the human ADRB3 after infection with a recombinant adenovirus. Conditioned media from noninfected CM or CM infected with GFP were used as controls. Note that heterologous expression of ADRB3 did not alter the expression of endogenous Adrb1 or Adrb2 in CM (see Supplementary material online, Figure S1E and F). When control CM (non-infected or GFPexpressing) were pre-stimulated with the alpha-adrenergic agonist, phenylephrine (PE), their conditioned media induced proliferation ( Figure 3B ) and myofibroblasts differentiation (detected as alphasmooth muscle actin expression, Figure 3D and E), but no significant effect on migration ( Figure 3C ) in superfused cardiac fibroblasts.
Further analysis of superfused fibroblasts showed that conditioned media from PE-stimulated myocytes activated ERK1/2 phosphorylation, procollagen type 1 mRNA and collagen type 1 protein expression (see Supplementary material online, Figure S5 ).
In contrast with control PE-treated cardiac myocytes, the above effects on proliferation, differentiation, ERK1/2 phosphorylation and collagen type 1 expression were not observed in fibroblasts superfused with culture media conditioned by PE-treated cardiac myocytes after adenoviral expression of the human ADRB3.
Proteomic analysis of the cardiac myocytes 'secretome'
As these effects of the media conditioned by PE-stimulated CM were abrogated after heating inactivation (see Supplementary material online, Figure S5D and E), they most probably involved peptide (or peptide-associated) factors in the secretome of CM. In order to identify putative paracrine factors, the conditioned media from GFP-or ADRB3-expressing cardiac myocytes treated (or not) with PE were submitted to shotgun proteomic analysis by liquid chromatography tandem mass spectrometry. Several filters were used to retain only candidate proteins for which solid sequence identification was obtained based on a minimum of two peptides fragments. Principal component analysis allowed to segregate a limited number of candidates. By comparing the variation of candidate proteins that were statistically different between the secretomes of PE-stimulated myocytes expressing GFP vs. ADRB3, a number of up-or down-regulated proteins were listed ( Table 1) , starting with the most strongly divergent ones. High in the list was CTGF/CCN2, which appeared to be strongly downregulated in the secretome of ADRB3-expressing myocytes. Direct measurement of CTGF by ELISA in the secretomes (see Supplementary material online, Figure S6A ) confirmed significantly lower CTGF content in the media from ADRB3-expressing cardiac myocytes (compared with GFP) after PE stimulation. Moreover, analysis of extracts of PE-treated cardiac myocytes showed lower Ctgf transcripts and CTGF proteins abundance upon ADRB3 (vs GFP) expression (see Supplementary material online, Figure S6B and C) . Likewise, activation of endogenous beta3AR (i.e. in non-transfected cardiac myocytes) with the beta3AR-specific agonist, CL316243, resulted in significantly reduced Ctgf transcripts levels upon PE treatment (see Supplementary material online, Figure S6D) .
To validate the functional importance of CTGF as paracrine mediator for the effect of PE, CTGF expression was downregulated by siRNA in cardiac myocytes and their conditioned media tested on fibroblasts (see Supplementary material online, Figure S6E and G). Conditioned media from PE-and siRNA-treated myocytes reduced procollagen 1 expression (see Supplementary material online, Figure  S6F ) (without effect on proliferation, Figure 6E ) in superfused fibroblasts (compared with controls). Next, we examined the effect of cardiac ADRB3 on CTGF expression in our transgenic models in vivo. As shown in Figure 4A and B, upon TAC, the expression of CTGF was decreased in cardiac extracts from ADRB3-tg ( Figure 4A ), but significantly increased in hearts from TAM-treated alpha-MHCMerCreMer 0/þ ; Adrb3 flox/flox ( Figure 4B ), compared with controls.
Reactive oxygen species-dependent production of connective tissue growth factor in cardiac myocytes: role of beta3AR
The expression of CTGF in fibroblasts is regulated by reactive oxygen species (ROS)-dependent signalling. [12] [13] [14] Accordingly, when ROS measurements from all mice in our models were correlated with collagen volume fraction (CVF) in the same hearts, linear regression analysis showed a proportional increase in CVF with higher ROS production (see Supplementary material online, Figure S7E ). Further, we observed that treatment of cardiac myocytes with the antioxidant N-acetyl-cysteine (NAC) abrogated their expression of CTGF upon PE stimulation (see Supplementary material online, Figure S7A ); and that superfusion of fibroblasts with culture media from such NAC-treated myocytes inhibited their expression of procollagen type 1 (see Supplementary material online, Figure S7B ). Therefore, we reasoned that beta3AR expression may exert antioxidant effects in cardiac myocytes resulting in less expression of CTGF under stress. We verified this in homotypic cultures of GFPor ADRB3-expressing cardiac myocytes, in which ADRB3 expression significantly reduced ROS production after PE stimulation (see Supplementary material online, Figure S7C ). Consistently, myocardial ROS production was significantly reduced in ADRB3-TG after TAC (see Supplementary material online, Figure S7D ) compared with WT.
Neuronal nitric oxide synthase mediates anti-oxidant effects downstream beta3-adrenergic receptor and beta3-adrenergic receptor's protective paracrine effects
We next tested whether NOS downstream beta3AR is involved in this anti-oxidant protection. As shown in Figure 5A , specific nNOS inhibition with N5-(1-imino-3-butenyl)-L-ornithine (L-VNIO) increased the ROS signals and, importantly, abrogated the protective effect of beta3AR expression. This suggested that the anti-oxidant effect of beta3AR is mediated by activation of nNOS in cardiac myocytes. To verify the impact of nNOS-mediated anti-oxidant effect on paracrine signalling, culture media conditioned by myocytes treated (or not) with L-VNIO and stimulated with PE were incubated on fibroblasts, from which the expression of procollagen type 1 was measured. As shown in Figure 5B , co-treatment of myocytes with L-VNIO and PE fully abrogated the inhibitory effect of beta3AR on procollagen 1 expression in fibroblasts (whereas L-VNIO alone had no independent effect). We confirmed the involvement of nNOS by analysing ROS production from myocardial extracts from ADRB3-tg (vs WT) mice submitted (or not) to TAC ( Figure 5C) ; treatment of extracts with L-VNIO strongly increased ROS signals from TAC hearts and, notably, abrogated the protection previously observed in ADRB3-tg. To add genetic proof of the causal involvement of Nos1, we cross-bred our ADRB3-tg with Nos1 -/-mice and examined their phenotype at 3 weeks post-TAC (compared to their respective controls). As shown in Figure 5D , although ADRB3
developed less fibrosis than WT/Nos1 þ/þ (WT/WT) controls, illustrating again the protection by cardiac ADRB3 expression, this protection was completely lost in ADRB3
compared with WT/Nos1 -/-(WT/nNOS KO).
Beta3-adrenergic receptor expression is inversely related with myocardial fibrosis in human ventricular biopsies
Finally, we compared the abundance of ADRB3 mRNA and myocardial fibrosis, measured as COL1A1 and COL3A1 mRNA expression ex vivo in ventricular biopsies obtained at the time of operation in patients that underwent valve surgery. Patients characteristics are reported in Supplementary material online, Table S1 . As shown in Figure  6A , the expression of ADRB3 was almost double in biopsies with the lowest COL1A1 levels, and a similar trend was seen in biopsies with lowest COLIA3 (Figure 6B ). Of note, CTGF expression was also closely related to COL1A1 ( Figure 6C ) and COLIA3 ( Figure 6D ) expression in the same biopsies.
Discussion
The main findings of this study are as following; (i) expression of the human ADRB3 in cardiac myocytes (ADRB3-tg) attenuates cardiac induced cardiac fibrosis; (iii) the protection by ADRB3 expression is replicated by superfusion of cardiac fibroblasts with the secretome of ADRB3-expressing myocytes, implying that beta3AR modulates paracrine signalling to attenuate the pro-fibrotic phenotype; (iv) proteomic analysis of the secretome from ADRB3-expressing cardiac myocytes identifies downregulation of several secreted growth factors or matricellular proteins involved in fibrosis; among these, CTFG production is reduced by ADRB3 expression in myocytes in vitro and in vivo after TAC; (v) this reduction is mediated by the anti-oxidant effect of beta3AR through its coupling to neuronal NOS (nNOS); (vi) accordingly, the beta3AR protection from TAC-induced fibrosis is lost in Nos1-deficient mice ( Figure 7) ; (vii) in human ventricular biopsies, ADRB3 expression is inversely related to the degree of myocardial fibrosis.
The pattern of diffuse fibrosis post-TAC is accompanied with early proliferation (Days 4-7) of specific resident fibroblasts populations in situ. This underscores the importance of local paracrine signalling for the control of the fibrogenic response, as suggested from our data. Several signalling peptides were identified as differentially regulated by the beta3AR in the myocyte secretome, many of which regulate TGFbeta signalling, such as the latent TGFbeta-binding protein 2 ( Table 1) . CTGF (CCN2), also downregulated by the beta3AR in our study, has been widely implicated in fibrogenesis in many organs, including the heart. 15 Although both cytokines can be produced by cardiac myocytes, CTGF does not simply replicate or function as a downstream effector of TGFbeta signalling but its effects vary according to the type of stress or cytokines context. 16 Accordingly, genetic models with cardiac-specific CTGF overexpression [17] [18] [19] or
Ctgf deletion 19 have yielded divergent remodeling phenotypes depending on the type of stress imposed (e.g. ischaemia/reperfusion vs. Angiotensin II infusion vs. TAC). Nevertheless, cardiac-specific Ctgf deletion did attenuate fibrosis in the context of TAC and TGFbeta overexpression. 19 Likewise, siRNA downregulation of Ctgf in our study significantly attenuated the pro-fibrotic effect of PE (see Supplementary material online, Figure S6 ), albeit not completely. Although compensatory increases in other factors probably account for the incomplete phenotypes in these genetic experiments, this also underscores the role of CCN2 as a modulator, rather than mediator of cardiac fibrosis. As other members of the CCN group, CCN2 contains four distinct modules, including a thrombospondin homology domain (module III) and heparin binding domain (module IV) that enable its modulation of the signalling of other co-secreted molecules. 20 One of these is thrombospondin-1 (TSP1) 21 that was Figure 6 The abundance of beta3AR is inversely related to myocardial fibrosis in human ventricular biopsies from patients with valvular disease. similarly down-regulated as CCN2 by ADRB3 expression in our model. TSP1 and CCN2 also control extracellular matrix deposition, consistent with our observation of parallel downregulation of fibronectin, collagen type 1 and 3, laminin and fibrillin-1 ( Table 1) . Another regulator of extracellular matrix remodelling, Plasminogen Activator Inhibitor-1 (PAI1) was also downregulated by ADRB3 expression. Notably, PAI1 expression is activated by systemic NOS inhibition 22 and downregulated by administration of blocking antibodies targeting CCN2/CTGF in the TAC model, 23 suggesting that cardiac NOS may prevent fibrosis by inhibiting CCN2/CTGF and subsequent PAI-1 and collagen production. As shown in the Table 1 , ADRB3 expression reciprocally increased the expression of chondroitin sulfate proteoglycan 4 (also known as NG2).NG2 binds PDGF-AA 24 and promotes angiogenesis through autocrine regulation of VEGF expression. 25 Upregulation of NG2 by ADRB3 could explain our previous observations of pro-angiogenic effects of beta3AR activation. 26 Cardiac fibrosis and CTGF expression were correlated with ROS in our models, as observed by others e.g. in human myxomatous mitral valve remodelling. 13 Notably, both were exacerbated upon nNOS inhibition, which also abrogated the protection by ADRB3 expression in vitro and in vivo. We and others previously demonstrated beta3AR coupling to NOS in cardiac myocytes, 27, 28 including eNOS and nNOS. 29, 30 The latter protects eNOS from oxidative uncoupling by S-glutathionylation, thereby maintaining NO biovailability and downstream signalling. 31 nNOS, in turn, was shown to inhibit ROS production in cardiac myocytes through cGMP-dependent inactivation of xanthine oxidoreductase. 32 The relevance of these findings to human cardiac remodelling is reinforced by our additional observation that myocardial fibrosis is lower in patients with higher ADRB3 expression in ventricular biopsies. We had previously shown that contrary to beta1-2ARs, the expression of beta3AR is upregulated in stressed cardiac myocytes from rodents 33 and humans, 34 possibly as a protective mechanism.
Notably, the coupling of beta3AR may be preserved under adrenergic stress because of relative resistance to desensitization. 35 This makes beta3AR an attractive target for the therapeutic use of new, more specific beta3AR agonists currently in clinical use for noncardiovascular indications. 36 One of these, mirabegron, is currently tested for 're-purposing' in patients with structural cardiac disease at risk of developing heart failure with preserved ejection fraction (ClinicalTrials.gov NCT02599480), for which myocardial fibrosis is a key pathogenic factor. Of note, beta3AR is robustly expressed in human atrial muscle, 37 where ROS and fibrosis are clearly implicated in the generation and maintenance of atrial fibrillation 38, 39 Therefore, our findings may guide future therapeutic uses of current and new specific beta3AR agonists for myocardial protection.
Supplementary material
Supplementary material is available at European Heart Journal online.
Figure 7
Cardiac beta3AR modulates stress-induced paracrine signaling to fibroblasts. Haemodynamic or neurohormonal stress on cardiac myocytes induces their production of cytokines and matricellular proteins that activate fibroblasts, resulting in interstitial fibrosis. Cardiac beta3AR modulates paracrine signals to reduce fibrosis. In particular, beta3AR coupling to neuronal nitric oxide synthase reduces stress-induced ROS production and downstream Ctgf/Ccn2 transcripts and protein expression (among others), thereby attenuating the synergistic effects of CTGF on paracrine pro-fibrotic factors.
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